Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleARTICLE

Activation of Endothelial Nitric-Oxide Synthase by Tumor Necrosis Factor-α: A Novel Pathway Involving Sequential Activation of Neutral Sphingomyelinase, Phosphatidylinositol-3′ kinase, and Akt

Rico Barsacchi, Cristiana Perrotta, Stefania Bulotta, Salvador Moncada, Nica Borgese and Emilio Clementi
Molecular Pharmacology April 2003, 63 (4) 886-895; DOI: https://doi.org/10.1124/mol.63.4.886
Rico Barsacchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiana Perrotta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Bulotta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salvador Moncada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nica Borgese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilio Clementi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Activation of endothelial nitric-oxide synthase (eNOS) has been shown to occur through various pathways involving increases in the cytosolic Ca2+ concentration, activation of the phosphatidylinositol-3′ kinase/Akt pathway, as well as regulation by other kinases and by protein-protein interactions. We have recently reported that eNOS, expressed in an inducible HeLa Tet-off cell line, is activated by tumor necrosis factor-α (TNF-α) in a previously undescribed pathway that involves the lipid messenger ceramide. We have now characterized this pathway. We report here that eNOS activation in response to TNF-α correlated with phosphorylation of Akt at Ser 473 and of eNOS itself at Ser 1179. Akt and eNOS phosphorylation, as well as eNOS activation, were blocked by inhibitors of both phosphatidylinositol-3′ kinase and neutral sphingomyelinase. In contrast, although acid sphingomyelinase was also stimulated by TNF-α, its inhibition was without effect. The activation of neutral sphingomyelinase triggered by TNF-α was insensitive to phosphatidylinositol-3′ kinase inhibitors. Taken together, these results indicate that eNOS activation by TNF-α occurs through sequential activation of neutral sphingomyelinase and of the phosphatidylinositol-3′ kinase/Akt pathway. The time course of eNOS activation induced through this pathway was markedly different from that triggered by ATP and epidermal growth factor, which activate eNOS through an increase in intracellular Ca2+ concentration and through a sphingomyelinase-independent stimulation of the phosphatidylinositol-3′ kinase/Akt pathway, respectively. The novel pathway of activation of eNOS described here may have broad biological relevance because neutral sphingomyelinase is activated not only by TNF-α but also by a variety of other physiological and pathological stimuli.

Footnotes

  • This work was supported by grants from the Italian Association for Cancer Research (E.C.); cofinanziamento 2001 from the Ministero dell'Istruzione, dell'Università e della Ricerca (E.C. and J. Meldolesi), and the Medical Research Council in the UK (S.M.).

  • Abbreviations:
    eNOS
    endothelial nitric oxide synthase
    PI3K
    phosphatidyl-inositol 3′ kinase
    TNF-α
    tumor necrosis factor-α
    TNF-RI
    55-kDa tumor necrosis factor-α receptor
    [Ca2+]c
    cytosolic Ca2+concentration
    SMase
    sphingomyelinase
    Ab
    antibody
    PDMP
    dl-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
    D609
    tricyclodecan-9-yl xanthate
    A-SMase
    acid sphingomyelinase
    N-SMase
    neutral sphingomyelinase
    LY 294002
    2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
    l-NAME
    Nω-nitro-l-arginine methyl ester
    EGF
    epidermal growth factor
    Fum B1
    fumonisin B1
    • Received August 26, 2002.
    • Accepted January 3, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 63 (4)
Molecular Pharmacology
Vol. 63, Issue 4
1 Apr 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activation of Endothelial Nitric-Oxide Synthase by Tumor Necrosis Factor-α: A Novel Pathway Involving Sequential Activation of Neutral Sphingomyelinase, Phosphatidylinositol-3′ kinase, and Akt
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleARTICLE

Activation of Endothelial Nitric-Oxide Synthase by Tumor Necrosis Factor-α: A Novel Pathway Involving Sequential Activation of Neutral Sphingomyelinase, Phosphatidylinositol-3′ kinase, and Akt

Rico Barsacchi, Cristiana Perrotta, Stefania Bulotta, Salvador Moncada, Nica Borgese and Emilio Clementi
Molecular Pharmacology April 1, 2003, 63 (4) 886-895; DOI: https://doi.org/10.1124/mol.63.4.886

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleARTICLE

Activation of Endothelial Nitric-Oxide Synthase by Tumor Necrosis Factor-α: A Novel Pathway Involving Sequential Activation of Neutral Sphingomyelinase, Phosphatidylinositol-3′ kinase, and Akt

Rico Barsacchi, Cristiana Perrotta, Stefania Bulotta, Salvador Moncada, Nica Borgese and Emilio Clementi
Molecular Pharmacology April 1, 2003, 63 (4) 886-895; DOI: https://doi.org/10.1124/mol.63.4.886
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

ARTICLE

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more ARTICLE

Article

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Article

Articles

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics